Is Harmony Biosciences Holdings, Inc. (HRMY) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 10.0% / 30% | 47.3% / 30% | 5.9% / 30% | 2.52% / 5% | ✗ NOT HALAL |
| DJIM | 10.0% / 33% | 47.3% / 33% | 5.9% / 33% | 2.52% / 5% | ✗ NOT HALAL |
| MSCI | 12.9% / 33% | 61.0% / 33% | 7.6% / 33% | 2.52% / 5% | ✗ NOT HALAL |
| S&P | 10.0% / 33% | 47.3% / 33% | 5.9% / 33% | 2.52% / 5% | ✗ NOT HALAL |
| FTSE | 12.9% / 33% | 61.0% / 33% | 7.6% / 50% | 2.52% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 77.2% | |
| Operating Margin | 15.8% | |
| Net Margin | 18.3% | |
| Return on Equity (ROE) | 20.8% | |
| Return on Assets (ROA) | 11.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $348M |
| Free Cash Flow | $348M |
| Total Debt | $164M |
| Debt-to-Equity | 19.4 |
| Current Ratio | 3.6 |
| Total Assets | $1.3B |
Price & Trading
| Last Close | $27.44 |
| 50-Day MA | $32.21 |
| 200-Day MA | $33.38 |
| Avg Volume | 858K |
| Beta | 0.9 |
|
52-Week Range
$25.52
| |
About Harmony Biosciences Holdings, Inc. (HRMY)
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Harmony Biosciences Holdings, Inc. (HRMY) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Harmony Biosciences Holdings, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Harmony Biosciences Holdings, Inc.'s debt ratio?
Harmony Biosciences Holdings, Inc.'s debt ratio is 10.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 12.9%.
What are Harmony Biosciences Holdings, Inc.'s key financial metrics?
Harmony Biosciences Holdings, Inc. has a market capitalization of $1.5B, trailing P/E ratio of 9.8, and revenue of $868M. The company maintains a gross margin of 77.2% and a net margin of 18.3%. Return on equity stands at 20.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.